Literature DB >> 19291367

The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study).

Jack L Martin1, Edward T A Fry, Todd Martin, Trevor H Atherley, Seth S Martin, Marvin J Slepian.   

Abstract

OBJECTIVE: We evaluated the early pharmacodynamic profile of the combined 30 mg intravenous and 1 mg/kg subcutaneous enoxaparin loading utilized in the TIMI 11B and ExTRACT TIMI 25 trials.
BACKGROUND: It has not been reported whether anti-Xa levels appropriate for percutaneous coronary intervention (PCI) can be reliably achieved within 2 h utilizing this regimen.
METHODS: Twenty-six patients with acute coronary syndrome (ACS) treated with this regimen had anti-Xa levels measured at 5 min, 2, 4, 6 and 8 h.
RESULTS: Seventy-six percent of patients had anti-Xa levels above 0.5 IU/ml at 5 min. Dose-response curves showed all patients to have anti-Xa levels above 0.5 IU/ml within 1 h. Anti-Xa remained in the targeted range for PCI (0.5 to 1.8 IU/ml) at 2, 4, 6 and 8 h in all patients.
CONCLUSION: This regimen is well suited for ACS treatment with an invasive strategy, including the rapid transition to early and rescue PCI.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291367     DOI: 10.1007/s11239-009-0326-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  22 in total

1.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

2.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

Review 3.  Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.

Authors:  D J Fintel; G S Ledley
Journal:  Clin Cardiol       Date:  2000-09       Impact factor: 2.882

4.  Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.

Authors:  Silvio Zalc; Pedro A Lemos; Antonio Esteves; Expedito E Ribeiro; Pedro Horta; Jose C Nicolau; Jose A F Ramires; Marc Cohen; Eulogio E Martinez
Journal:  J Invasive Cardiol       Date:  2006-02       Impact factor: 2.022

5.  Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.

Authors:  D J Kereiakes; C Grines; E Fry; P Esente; D Hoppensteadt; M Midei; L Barr; W Matthai; M Todd; T Broderick; R Rubinstein; J Fareed; E Santoian; A Neiderman; B Brodie; J Zidar; J J Ferguson; M Cohen
Journal:  J Invasive Cardiol       Date:  2001-04       Impact factor: 2.022

6.  Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial.

Authors:  Gilles Montalescot; Marc Cohen; Genevieve Salette; Walter J Desmet; Carlos Macaya; Philip E G Aylward; Ph Gabriel Steg; Harvey D White; Richard Gallo; Steven R Steinhubl
Journal:  Eur Heart J       Date:  2008-02       Impact factor: 29.983

7.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Authors:  James J Ferguson; Robert M Califf; Elliott M Antman; Marc Cohen; Cindy L Grines; Shaun Goodman; Dean J Kereiakes; Anatoly Langer; Kenneth W Mahaffey; Christopher C Nessel; Paul W Armstrong; Alvaro Avezum; Phil Aylward; Richard C Becker; Luigi Biasucci; Steven Borzak; Jacques Col; Marty J Frey; Ed Fry; Dietrich C Gulba; Sema Guneri; Enrique Gurfinkel; Robert Harrington; Judith S Hochman; Neal S Kleiman; Martin B Leon; Jose Luis Lopez-Sendon; Carl J Pepine; Witold Ruzyllo; Steven R Steinhubl; Paul S Teirstein; Luis Toro-Figueroa; Harvey White
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

8.  Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.

Authors:  C Michael Gibson; Sabina A Murphy; Gilles Montalescot; David A Morrow; Diego Ardissino; Marc Cohen; Dietrich C Gulba; Oscar H Kracoff; Basil S Lewis; Nathan Roguin; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-05-25       Impact factor: 24.094

9.  Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen.

Authors:  Sargis Khoobiar; Nicolai Mejevoi; Khalil Kaid; Catalin Boiangiu; Sampoornima Setty; Anjum Tanwir; Khaula Khalid; Marc Cohen
Journal:  J Thromb Thrombolysis       Date:  2008-07-18       Impact factor: 2.300

10.  The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes.

Authors:  Nick R Bijsterveld; Arno H Moons; Joost C M Meijers; Marcel Levi; Harry R Büller; Ron J G Peters
Journal:  J Am Coll Cardiol       Date:  2003-08-06       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.